Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution.
Brain metastases
Cerebrospinal fluid
Leptomeningeal metastases
Next-generation sequencing
Systemic disease progression
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
11
03
2022
revised:
28
07
2022
accepted:
08
12
2022
entrez:
16
1
2023
pubmed:
17
1
2023
medline:
17
1
2023
Statut:
epublish
Résumé
Metastases to the central nervous system (CNS) are devastating neurological complications. Circulating cell-free tumor DNA (ctDNA) from cerebrospinal fluid (CSF) better represents genomic alterations in CNS tumors compared to plasma (PLA). However, the clinical value of cerebrospinal fluid (CSF) as a liquid biopsy medium in non-small cell lung cancer patients with leptomeningeal metastases (NSCLC-LM), regardless of extracranial evolution, remains unclear. 14/48 NSCLC-BM patients and 34/48 NSCLC-LM patients were enrolled in this study. The genomic mutation profiles in CSF and matched PLA for patients with single CNS progression (cohort one, N = 22) or intracranial progression with extracranial disease progression (cohort two, N = 12) were compared. ctDNA in the CSF and simultaneously collected PLA was subjected to next-generation target sequencing (NGS) of 168 cancer-relevant genes. CSF is more comprehensive of driver genomic mutation profile than in matched PLA in patients with a single CNS progression. In addition, potential prognostic markers are much higher in CSF samples than related PLA. For example, the detection rate of For NSCLC -LM patients, regardless of single intracranial progression or intracranial progression simultaneously with extracranial evolution, CSF is superior to matched PLA.
Identifiants
pubmed: 36643302
doi: 10.1016/j.heliyon.2022.e12374
pii: S2405-8440(22)03662-3
pmc: PMC9834711
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12374Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Clin Lung Cancer. 2018 Jul;19(4):e373-e379
pubmed: 29526531
J Thorac Oncol. 2016 Nov;11(11):1962-1969
pubmed: 27539328
Am J Respir Crit Care Med. 2020 Mar 15;201(6):697-706
pubmed: 31747302
Thorac Cancer. 2020 Mar;11(3):588-593
pubmed: 31944608
JAMA Netw Open. 2020 Aug 3;3(8):e209077
pubmed: 32749467
Target Oncol. 2018 Oct;13(5):621-629
pubmed: 30284706
Pharmacogenomics. 2015 Nov;16(16):1843-62
pubmed: 26555006
Nat Commun. 2015 Nov 10;6:8839
pubmed: 26554728
Oncol Lett. 2017 May;13(5):3335-3341
pubmed: 28521440
Sci Rep. 2020 Nov 20;10(1):20243
pubmed: 33219256
Clin Cancer Res. 2010 Dec 1;16(23):5873-82
pubmed: 21030498
Curr Oncol Rep. 2012 Feb;14(1):48-54
pubmed: 22012633
Mol Oncol. 2019 Dec;13(12):2633-2645
pubmed: 31529604
Mol Diagn Ther. 2021 Mar;25(2):207-229
pubmed: 33646562
Clin Cancer Res. 2015 Jul 15;21(14):3196-203
pubmed: 25829397
Clin Cancer Res. 2020 Jun 1;26(11):2535-2545
pubmed: 32086345